Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ionis Pharmaceutical (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,897,894
  • Shares Outstanding, K 137,572
  • Annual Sales, $ 507,670 K
  • Annual Income, $ -5,970 K
  • 36-Month Beta 2.28
  • Price/Sales 13.23
  • Price/Cash Flow 160.73
  • Price/Book 9.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.04
  • Number of Estimates 7
  • High Estimate 0.23
  • Low Estimate -0.27
  • Prior Year 0.02
  • Growth Rate Est. (year over year) -300.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.99 +6.33%
on 01/30/19
60.92 -5.76%
on 02/13/19
-0.62 (-1.07%)
since 01/18/19
3-Month
48.27 +18.94%
on 12/24/18
60.92 -5.76%
on 02/13/19
+3.65 (+6.79%)
since 11/21/18
52-Week
39.07 +46.94%
on 05/08/18
60.92 -5.76%
on 02/13/19
+7.55 (+15.14%)
since 02/21/18

Most Recent Stories

More News
Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IONS : 57.41 (-1.64%)
Amyloidosis Treatment Market In- depth Analysis & Recent Developments, (2019-2025)

investigations of critical facets of this Amyloidosis Treatment market predicated on present industry events, market requirements, industry approach endorsed by Amyloidosis Treatment market players along...

VRX.TO : 30.80 (-3.33%)
AZN : 40.43 (-0.25%)
JNJ : 135.42 (-0.68%)
IONS : 57.41 (-1.64%)
TKPYY : 16.5900 (-0.90%)
CELGZ : 0.85 (+11.84%)
GSK : 40.54 (-1.98%)
PFE : 42.14 (-0.14%)
Akcea Therapeutics to Present at Upcoming Investor Conferences

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that...

AKCA : 25.45 (-3.05%)
IONS : 57.41 (-1.64%)
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast

Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February 26 at 4:30 p.m. Eastern Time to discuss its fourth...

AKCA : 25.45 (-3.05%)
IONS : 57.41 (-1.64%)
Ionis Pharmaceuticals to Hold 2018 Financial Results Webcast

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 27th at 11:30 a.m. Eastern Time to discuss its 2018 financial results and report on pipeline...

IONS : 57.41 (-1.64%)
Has Ionis Pharmaceuticals (IONS) Outpaced Other Medical Stocks This Year?

Is (IONS) Outperforming Other Medical Stocks This Year?

IONS : 57.41 (-1.64%)
First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that its partner Roche, also known as Genentech in the United States, has enrolled the first patient in...

IONS : 57.41 (-1.64%)
Ironwood Commences Phase I Study on IW-6463 for CNS Disorders

Ironwood (IRWD) begins a phase I study on CNS-penetrant soluble guanylate cyclase stimulator, IW-6463, for treating severe CNS disorders.

IRWD : 14.18 (-0.84%)
AGN : 136.60 (-2.66%)
HKMPF : 22.1000 (-1.78%)
IONS : 57.41 (-1.64%)
4 Defensive Stocks to Buy Amid Shutdown and Brexit

Defensive equities could ride out market unpredictability.

NWL : 17.29 (+0.82%)
NBIX : 77.31 (-2.58%)
IONS : 57.41 (-1.64%)
TUP : 30.70 (-0.65%)
Pfizer Gets FDA's Priority Review for Rare Disease Candidate

FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

AKCA : 25.45 (-3.05%)
ALNY : 76.21 (-1.98%)
IONS : 57.41 (-1.64%)
PFE : 42.14 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade IONS with:

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Key Turning Points

2nd Resistance Point 58.79
1st Resistance Point 58.10
Last Price 57.41
1st Support Level 56.85
2nd Support Level 56.29

See More

52-Week High 60.92
Last Price 57.41
Fibonacci 61.8% 52.57
Fibonacci 50% 49.99
Fibonacci 38.2% 47.42
52-Week Low 39.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar